Skip to main content

Table 1 Characteristics of patients with and without hemolytic anemia

From: Carboxyhemoglobin, a reliable diagnosis biomarker for hemolysis in intensive care unit: a retrospective study

 

Hemolytic anemia (94)

Non-hemolytic anemia (93)

p

General characteristics

 Age (years)

47 (32–62)

69 (59–77)

0.0004

 Women (%)

51

33

0.004

 Smokers (%)

34

37

0.9

 SOFA at admission

6 (3–7)

6 (4–9)

0.004

 Sepsis (%)

18

27

0.1

 Mechanical ventilation (%)

17

57

< 0.0001

 Catecholamines (norepinephrine) (%)

17

54

< 0.0001

 Extra-renal epuration (%)

17

13

0.43

 Length of stay in ICU (days)

6 (3–12)

7 (4–12)

0.54

 Mortality (%)

16

32

0.24

Cause of anemia (%)

 Hemolytic anemia (94)

  AIHA

26

  

  SCD

20

  

  TMA

54

  

 Non-hemolytic anemia (93)

  Bleeding

 

37

 

  Chronic renal failure

 

15

 

  Cytopenia

 

23

 

  Splenomegaly

 

10

 

  Other

 

15

 

Biological marker (blood)

 Hemoglobin (g/dL)

7.8 (6.2–9.1)

7.3 (6.5–8.1)

0.14

 White blood cells (× 109/L)

10.6 (7.8–17.9)

11.3 (6.7–16.5)

0.2

 Platelets (10 3/mm3)

76 (33.2–228)

141 (48–237)

0.09

 Mean corpuscular volume (fL)

88 (83–93)

88 (82–94)

0.47

 Reticulocytes (G/L)

134 (77–211)

55 (29–77)

0.0001

 LDH (UI/L)

1361 (866–2121)

536 (420–786)

0.46

 Unconjugated bilirubin (μmol/L)

27 (18–45)

15 (10–20)

< 0.0001

 Prothrombin time (%)

76 (62–89)

70 (57–80)

0.009

 Activated partial thromboplastin time ratio

1.07 (0.94–1.3)

1.17 (1.01–1.51)

0.055

 Creatinine (μmol/L)

102 (71–160)

122 (81–206)

0.47

 pH

7.44 (7.4–7.48)

7.44 (7.34–7.48)

0.25

 pO2 (mmHg)

87 (70–113)

81 (67–107)

0.92

 pCO2 (mmHg)

34 (31–43)

35 (30–42)

0.93

 Lactate (mmol/L)

1.3 (0.9–2.5)

1.25 (0.9–2.3)

0.88

 Carboxyhemoglobin (%)

3.0 (2.3–3.9)

1.6 (1.0–2.1)

< 0.0001

 Methemoglobin (%)

1.5 (1.2–1.8)

1 (0.7–1.4)

< 0.0001

  1. Data are expressed as number, percentage or median and interquartile ranges (IQRs)
  2. SOFA sepsis-related organ failure assessment, AIHA auto-immune hemolytic anemia, TMA thrombotic micro-angiopathy, SCD sickle cell disease, LDH lactate dehydrogenase